Sun to take Taro private after sweetened buy-out offer
This article was originally published in Scrip
India's Sun Pharmaceutical Industries is set to take Taro Pharmaceutical Industries private after a sweetened offer of $39.50 per share to acquire the remaining 34% not held by Sun in Taro was blessed by the Israeli firm's board. Sun expects to delist Taro from the New York Stock Exchange once the current proposal is executed.
You may also be interested in...
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.